Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 1.00 |
| ▸ | MTOR | P42345 | 7/20 | 0.79 |
| ▸ | AKT1 | P31749 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328708 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL1982992 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL1378921 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL1982988 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL1378925 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL1983001 | 0.92 | PIK3CA (1.00) | PIK3CAMTORAKT1 | |
| SCHEMBL3561236 | 0.89 | PIK3CA (0.84) | PIK3CAMTORAKT1 | |
| SCHEMBL3561233 | 0.87 | PIK3CA (0.82) | PIK3CAMTORAKT1 | |
| SCHEMBL3561237 | 0.87 | PIK3CA (0.82) | PIK3CAMTORAKT1 | |
| SCHEMBL1380099 | 0.87 | PIK3CA (1.00) | PIK3CAMTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008032162-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PIK3CA 3/4885MTOR 31/4885AKT1 23/4885 |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PIK3CA 3/4885MTOR 31/4885AKT1 23/4885 |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PIK3CA 3/4885MTOR 31/4885AKT1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.